STOCK TITAN
  1. Home
  2. News
  3. RHHBY

Roche Holding AG - RHHBY STOCK NEWS

Welcome to our dedicated news page for Roche Holding (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roche Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roche Holding's position in the market.

News
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Rhea-AI Summary
Roche reports a 2% increase in sales in the first quarter, with both pharmaceuticals and diagnostics divisions experiencing high single-digit growth excluding COVID-19 products. The company saw a 7% growth in pharmaceuticals driven by sales of medicines for severe diseases, while the diagnostics division grew by 8% due to demand for immunodiagnostic products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
covid-19
-
News
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Rhea-AI Summary
Roche's Alecensa receives FDA approval as the first adjuvant treatment for ALK-positive early-stage lung cancer, demonstrating a 76% risk reduction in disease recurrence or death based on Phase III ALINA study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
fda approval
-
News
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Rhea-AI Summary
The FDA has approved Genentech's Alecensa as the first adjuvant treatment for ALK-positive early-stage lung cancer. The approval is based on the Phase III ALINA study, demonstrating a 76% reduction in the risk of disease recurrence or death. This addresses a critical unmet need in this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
fda approval
News
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Rhea-AI Summary
Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS. The Phase III study results show that the subcutaneous injection is consistent with IV infusion and achieves near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks. The twice-yearly, 10-minute SC injection could expand OCREVUS usage to centers without IV infrastructure. Regulatory filings have been accepted by the FDA and EMA, with EU approval expected in mid-2024 and U.S. approval in September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
News
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
Rhea-AI Summary
Genentech's Columvi meets primary endpoint of overall survival in people with relapsed or refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO study, showing significant improvement in survival rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
clinical trial
-
News
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Rhea-AI Summary
Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
clinical trial
News
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Rhea-AI Summary
Roche's Elecsys pTau217 plasma biomarker test, developed in partnership with Eli Lilly and Company, receives Breakthrough Device Designation from the FDA. The test aims to identify amyloid pathology, aiding in early and accurate Alzheimer's diagnosis, potentially improving patient care and access to therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
-
News
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Rhea-AI Summary
Roche receives CE Mark approval for VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression, potentially benefiting from ENHERTU treatment. The test aids in assessing HER2-low status, expanding treatment options for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
News
Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
Rhea-AI Summary
Roche's cobas Malaria test receives FDA approval for screening U.S. blood donors, offering a sensitive solution to detect Plasmodium parasites and improve blood safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
fda approval
News
Roche Annual General Meeting 2024
Rhea-AI Summary
Roche shareholders approve all Board proposals, re-elect Severin Schwan as Chairman, and increase dividend for the 37th consecutive year. The company reports strong performance in Pharmaceuticals and Diagnostics Divisions with a focus on oncology, immunology, neurology, and new areas like obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Stock RHHBY logo
Roche Holding AG

OTC:RHHBY

RHHBY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

RHHBY Stock Data

199.10B
727.48M
0.15%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Basel